Charles Parry

Charles Parry

Auto-generated profile, based on publicly available information

Charles Parry

Cancer Research Horizons

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CPCharles W. Parry
Charles W. Parry
FPFrancesca Pellicano
Francesca Pellicano
ASAlexander W. Schüttelkopf
Alexander W. Schüttelkopf
KBKim S. Beyer
Kim S. Beyer
JBJustin Bower
Justin Bower
JTJohn Taylor
John Taylor

13 November 2024 in ChemRxiv
Verified
Preprint
Open access
PDF file
CPCharles Parry
Charles Parry
FPFrancesca Pellicano
Francesca Pellicano
ASAlexander W. Schüttelkopf
Alexander W. Schüttelkopf
KBKim Beyer
Kim Beyer
JBJustin Bower
Justin Bower
JTJohn Taylor
John Taylor
Activating mutations of Ras are one of the most prevalent drivers of cancer and are often associated with poor clinical outcomes. Despite FDA approval for two irreversible inhibitors that target the inactive state of KRasG12C, significant unmet clinical need still exists, and the susceptibility of non-G12C mutants to inactive-state inhibition remains unclear. Here we report the discovery of a novel series of reversible inhibitors that bind in an enlarged version of the switch I-II pocket with nanomolar affinities. Dependent on chemotype these can either preferentially bind to the inactive or active state or bind both with similar affinity. The active-state binders inhibit the Raf interaction for wild-type Ras, and a broad range of oncogenic KRas mutants with nanomolar potency. A sub-series of these molecules displays cellular inhibition of Ras-Raf binding, as well as decreased phosphorylation of the downstream protein ERK, demonstrating that potent pan-Ras inhibitors can be accessed from this novel pocket.